Clinical trial
A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects With Typical Werner Syndrome
NCT05847179 is registered in ClinicalTrials.gov with PRG Science & Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects With Typical Werner Syndrome
- Lead sponsor
- PRG Science & Technology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2027
- Enrollment
- 5 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.